Congress locks in drug discounts for safety-net clinics at checkout
H.R. 7391 — Community Health Center Drug Pricing Protection Act · Filed by Jack Bergman (R-MI) · 58 cosponsors · Introduced Feb 5, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill amends the 340B drug pricing program to require that Federally-qualified health centers (FQHCs) pay the statutory ceiling price for covered drugs at the point of purchase, not through later rebates or reconciliation. It bars manufacturers from charging FQHCs more upfront and then clawing back the difference later, ensuring these safety-net clinics get the discount immediately when they buy.
Why we flagged it
The bill's operative mechanism is a timing and pricing transparency requirement—it mandates that the discount be applied at point of purchase rather than through post-hoc reconciliation. This is a structural fix to the 340B program's mechanics, not a price-setting intervention, and it benefits public health providers' operational cash flow.
What the text implies
- Manufacturers may respond by tightening supply agreements, imposing volume minimums, or requiring pre-purchase commitments from FQHCs to manage their own cash flow under upfront pricing.
- The rule of construction in subsection (b) explicitly blocks 'later reconciliation by rebate, reimbursement, or other payment'—this forecloses a common industry practice and may trigger manufacturer litigation over contract interpretation.
- FQHCs' improved upfront cash position may enable faster inventory turnover and reduced working-capital borrowing, indirectly lowering their cost of operations and freeing capital for care expansion.
- The effective date applies to existing agreements 'beginning on the date of enactment'—this retroactively reinterprets existing contracts, creating potential disputes over whether prior agreements comply with the new standard.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
Federally-qualified health centers serve low-income and uninsured patients; upfront pricing at ceiling price strengthens their purchasing power and cash flow, allowing them to serve more patients or invest in care. The bill removes a financing burden that was effectively a hidden cost to safety-net providers and their patients.
Who stands to gain
- Federally-qualified health centers (FQHCs)
- Safety-net clinics and community health providers
Named in the bill
Federally-qualified health centers (FQHCs), Public Health Service Act, Section 340B, Pharmaceutical manufacturers, HHS Secretary
Where it stands
58 cosponsors: 40 Democrats, 18 Republicans.
- Feb 5, 2026 — Introduced · Congress.gov: “Introduced in House”
- Feb 5, 2026 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
10 lobbying clients named this bill on 10 disclosure filings across 2 quarters, Mar 2026 to Jun 2026. Those filings disclosed $10,408,000 in lobbying spend. A filing names 9 bills on average, so that figure is what each filing reported, not a share belonging to this bill.
More lobbying clients named this bill than 91% of bills with at least one filing.
Jack Bergman, the sponsor, reported $844,675 in PAC receipts in the 2026 cycle. $3,500 of that came from 1 PAC tied to these lobbying clients.
- Bristol-myers Squibb Company — $3,160,000 on 1 filing
- Amgen Inc — $2,440,000 on 1 filing
- Pfizer Inc. — $1,880,000 on 1 filing
- Johnson & Johnson Services Inc — $1,440,000 on 1 filing
- Gsk (fka Glaxosmithkline Inc.) — $890,000 on 1 filing
Lobbying Disclosure Act filings through Jul 24, 2026. A filing shows who paid to lobby on a bill it names, not what changed.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (1,832 characters) on Apr 14, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Mar 2026 to Jun 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Jul 24, 2026 · page rendered 2026-10-20.
“Congress locks in drug discounts for safety-net clinics at checkout” QuorumCivic. https://share.quorumcivic.app/bill/119/hr7391 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.